Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

08.06.16	Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention (GlobeNewswire)
08.06.16	Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016 (GlobeNewswire)
06.06.16	Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma (GlobeNewswire)
06.06.16	Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer (GlobeNewswire)
04.06.16	Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna® (GlobeNewswire)
02.06.16	Novartis drug Afinitor® receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET) (GlobeNewswire)
25.05.16	Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event (GlobeNewswire)
24.05.16	Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency (GlobeNewswire)
21.05.16	Novartis' Entresto® given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals (GlobeNewswire)
19.05.16	Novartis announces investment in FortiHFy clinical program of Entresto® and heart failure (GlobeNewswire)
18.05.16	Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting (GlobeNewswire)
18.05.16	MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer (GlobeNewswire)
17.05.16	Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis (GlobeNewswire)
17.05.16	Novartis fokussiert ihre Division Pharmaceuticals durch Schaffung der Geschäftseinheiten Novartis Pharmaceuticals und Novartis Oncology und beruft deren Leiter in die Geschäftsleitung von Novartis (GlobeNewswire)
17.05.16	Novartis Foundation and partners launch innovative hypertension program in Vietnam (GlobeNewswire)
15.05.16	Major study published in NEJM confirms Novartis' Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbations (GlobeNewswire)
29.04.16	Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors (GlobeNewswire)
28.04.16	Am 20. "Tag der Partnerschaft" engagieren sich weltweit über 27 500 Novartis Mitarbeitende in lokalen gemeinnützigen Projekten (GlobeNewswire)
28.04.16	Novartis celebrates 20th annual Community Partnership Day with more than 27,500 associates volunteering in their local communities (GlobeNewswire)
27.04.16	Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes (GlobeNewswire)
21.04.16	Novartis erzielt im ersten Quartal trotz Verlust der Exklusivrechte an Gleevec solide Ergebnisse und investiert in Neueinführungen zugunsten langfristigen Wachstums (GlobeNewswire)
21.04.16	Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth (GlobeNewswire)
20.04.16	Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex (GlobeNewswire)
08.04.16	Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's® nephrology indication (GlobeNewswire)
07.04.16	Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP (GlobeNewswire)
02.04.16	New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless... (GlobeNewswire)
02.04.16	Neue Analysen zeigen, dass Entresto(TM) von Novartis das Risiko für kardiovaskulären Tod oder Hospitalisierung wegen Herzinsuffizienz reduzierte und Patienten mit reduzierter Ejektionsfraktion... (GlobeNewswire)
31.03.16	Novartis publishes updated 2015 segment financials reflecting new division structure (GlobeNewswire)
05.03.16	Novartis' Cosentyx superior to Stelara in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeks (GlobeNewswire)
26.02.16	FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET) (GlobeNewswire)
23.02.16	Novartis shareholders approve all resolutions proposed by Board of Directors (GlobeNewswire)
23.02.16	Novartis Aktionäre genehmigen alle Anträge des Verwaltungsrats (GlobeNewswire)
19.02.16	Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML) (GlobeNewswire)
18.02.16	Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc. (GlobeNewswire)
12.02.16	Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA (GlobeNewswire)
11.02.16	Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim (GlobeNewswire)
31.01.16	Novartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination (GlobeNewswire)
27.01.16	Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations (GlobeNewswire)
27.01.16	Novartis erzielt 2015 eine kräftige Steigerung des Umsatzes und der Kern-gewinnmarge (kWk[1]); Pläne zur Wachstumsbeschleunigung bei Alcon und zur Straffung der Konzernaktivitäten bekannt gegeben (GlobeNewswire)
15.01.16	Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US (GlobeNewswire)
11.01.16	Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology (GlobeNewswire)
05.01.16	Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD (GlobeNewswire)
23.12.15	Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients (GlobeNewswire)
09.12.15	300 million child-friendly antimalarial treatments supplied without profit by Novartis (GlobeNewswire)
08.12.15	Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanercept (GlobeNewswire)
07.12.15	Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL (GlobeNewswire)
07.12.15	Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product (GlobeNewswire)
06.12.15	Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations (GlobeNewswire)
06.12.15	Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma (GlobeNewswire)
05.12.15	Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone
20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
20.12.24		Börse New York in Grün: So steht der NASDAQ 100 aktuell
20.12.24		SPI-Handel aktuell: SPI zum Handelsende leichter
20.12.24		Schwacher Handel: SMI schliesst mit Verlusten
20.12.24		Verluste in Europa: Euro STOXX 50 letztendlich leichter
20.12.24		Handel in Europa: STOXX 50 schliesst im Minus